成人B细胞前体急性淋巴细胞白血病染色体异常与拷贝数变异的预后影响:UKALL14研究
该研究在652例接受现代MRD驱动方案治疗的B细胞前体急性淋巴细胞白血病成人患者中评估了已知染色体异常和关键拷贝数变异(CNA)的预后影响。结果显示KMT2A-AFF1、复杂核型(CK)和低超二倍体/近三倍体(HoTr)患者复发率高、生存差,JAK-STAT异常与高复发率相关,而CNA缺失与生存无关。研究者据此提出修订的UKALL遗传学风险分类。
要点
- KMT2A-AFF1、CK和HoTr是强预后不良标志,复发率分别为50%、60%和53%。
- JAK-STAT异常(CRLF2、JAK2)见于6%患者,与高复发率(56%)相关。
- IKZF1、CDKN2A/B等CNA缺失或图谱与生存无关,原发遗传学异常预后价值更强。
核心结论
- 原发遗传学异常比继发性缺失是更强的预后标志物。
- 基于关键染色体异常提出修订的UKALL遗传学风险分类。
研究设计与样本
- 研究纳入652例接受现代MRD驱动方案治疗的B细胞前体ALL成人患者。
- 评估已知染色体异常和关键CNA的预后影响。
- CNA分析在436例患者中进行。
主要发现
- KMT2A-AFF1、CK和HoTr患者复发率分别为50%、60%和53%,生存相应较差。
- BCR-ABL1患者结局与其他患者相似。
- JAK-STAT异常(CRLF2、JAK2)见于6%患者,复发率56%。
- ABL类融合罕见(1%),ZNF384融合患者(n=12)生存极好。
- IKZF1、CDKN2A/B、PAX5、BTG1、ETV6、EBF1、RB1和PAR1的CNA缺失或图谱与生存无关。
关键数值与推荐
- 极高危:CK、HoTr或JAK-STAT异常。
- 高危:KMT2A融合。
- 酪氨酸激酶激活:BCR-ABL1和ABL类融合。
- 标危:所有其他患者。
临床怎么用
- 依据修订的UKALL遗传学风险分类对成人B细胞前体ALL进行危险分层。
- 对极高危和高危患者考虑强化治疗或移植策略。
- 继发性CNA缺失不宜单独用于预后分层。
局限性
- CNA分析仅覆盖436例患者,样本量有限。
- ZNF384融合亚组仅12例,结论需更大样本验证。
- 研究基于UKALL14方案,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chromosomal abnormalities are established prognostic markers in adult ALL. We assessed the prognostic impact of established chromosomal abnormalities and key copy number alterations (CNA) among 652 patients with B-cell precursor ALL treated on a modern MRD driven protocol. Patients with KMT2A-AFF1, complex karyotype (CK) and low hypodiploidy/near-triploidy (HoTr) had high relapse rates 50%, 60% & 53% and correspondingly poor survival. Patients with BCR-ABL1 had an outcome similar to other patients. JAK-STAT abnormalities (CRLF2, JAK2) occurred in 6% patients and were associated with a high relapse rate (56%). Patients with ABL-class fusions were rare (1%). A small group of patients with ZNF384 fusions (n = 12) had very good survival. CNA affecting IKZF1, CDKN2A/B, PAX5, BTG1, ETV6, EBF1, RB1 and PAR1 were assessed in 436 patients. None of the individual deletions or profiles were associated with survival, either in the cohort overall or within key subgroups. Collectively these data indicate that primary genetic abnormalities are stronger prognostic markers than secondary deletions. We propose a revised UKALL genetic risk classification based on key established chromosomal abnormalities: (1) very high risk: CK, HoTr or JAK-STAT abnormalities; (2) high risk: KMT2A fusions; (3) Tyrosine kinase activating: BCR-ABL1 and ABL-class fusions; (4) standard risk: all other patients.
引用
- Moorman AV, Barretta E, Butler ER, et al. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia. 2021. PMID: 34657128. doi:10.1038/s41375-021-01448-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。